CSIMarket Company Name, Ticker, Suppliers, else..
 
United Therapeutics Corporation  (NASDAQ: UTHR)
Other Ticker:  
 
 
Price: $358.9300 $-7.46 -2.036%
Day's High: $372.34 Week Perf: -1.09 %
Day's Low: $ 357.25 30 Day Perf: -3.73 %
Volume (M): 248 52 Wk High: $ 417.82
Volume (M$): $ 89,122 52 Wk Avg: $305.75
Open: $372.34 52 Wk Low: $208.62



 Market Capitalization (Millions $) 17,372
 Shares Outstanding (Millions) 48
 Employees 1,168
 Revenues (TTM) (Millions $) 2,756
 Net Income (TTM) (Millions $) 1,111
 Cash Flow (TTM) (Millions $) 446
 Capital Exp. (TTM) (Millions $) 239

United Therapeutics Corporation
United Therapeutics Corporation is a biotechnology company headquartered in Silver Spring, Maryland. The company is focused on the development, manufacturing, and commercialization of innovative therapies to treat rare disorders and life-threatening diseases. It was founded in 1996 by Martine Rothblatt.

The company has a diverse portfolio of products that includes both therapeutic drugs and wearable technology for remote patient monitoring. It conducts extensive research in pulmonary hypertension (PH), neuroblastoma, and hematologic cancers.

United Therapeutics operates in several business segments: commercial, research and development, and manufacturing. The company has a strong global presence and has offices and facilities in the United States, Europe, and Asia.

One of the key drugs developed by United Therapeutics is called Remodulin, which is used to treat pulmonary arterial hypertension (PAH). PAH is a rare and life-threatening condition that occurs when the blood vessels in the lungs become narrow, leading to high blood pressure and eventual heart failure. Remodulin is administered through a small pump that is connected to a catheter in the patientes chest.

Another drug developed by United Therapeutics is called Tyvaso, which is also used to treat PAH. Tyvaso is an inhaled medication that is delivered through a portable device.

In addition to developing therapies for PAH, United Therapeutics is actively researching treatments for neuroblastoma, a rare cancer that affects children, as well as hematologic cancers such as leukemia and lymphoma.

The company also offers wearable technology for remote patient monitoring. One of the most notable products is the TytoCare device, which allows patients to perform basic medical exams at home and share the data with their healthcare providers.

United Therapeutics has received numerous accolades for its contributions to the biotech industry. In 2017, the company was recognized as one of the worldes most innovative companies by Forbes magazine.

Overall, United Therapeutics Corporation is dedicated to improving the lives of patients with rare and life-threatening diseases through innovative research, manufacturing, and commercialization of high-quality therapies and medical devices.


   Company Address: 1000 Spring Street Silver Spring 20910 MD
   Company Phone Number: 608-9292   Stock Exchange / Ticker: NASDAQ UTHR


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BMY        1.68% 
JNJ        1.77% 
LLY   -9%    
MRK   -3.03%    
TEVA        7.24% 
VTRS   -4.24%    
• View Complete Report
   



Business Update

United Therapeutics Achieves Full Enrollment in TETON 2 Study Evaluating Inhaled Treprostinil for Idiopath...

Published Wed, Jul 10 2024 11:54 AM UTC

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, recently announced the completion of patient enrollment for the TETON 2 study. This significant milestone is part of their larger, global TETON clinical trial program aimed at evaluating the efficacy of Tyvaso (treprostinil) inhalation solution f...
United Therapeutics Corporation

Concerns arise as United Therapeutics Corporation experiences impressive earnings growth alongside troubling inventory and accounts receivable trends in the first quarter of 2024.

United Therapeutics Corporation (Nasdaq: UTHR) recently announced impressive financial results for the first quarter of 2024, with revenue increasing by over 33.695% to $677.70 million and EPS advancing by 26.95% to $6.17 per share year on year. While these numbers may seem positive on the surface, a deeper examination reveals some concerning trends that may indicate trouble ahead for the company.
One of the most alarming factors is the significant increase in inventories and supplies, which rose to $120.2 million in the first quarter of 2024. This suggests that United Therapeutics may be struggling to convert their products into sales, potentially leading to excess inventory and decreased profitability. Additionally, the build-up in accounts receivable to $307.3 million could indicate that the company is facing challenges in collecting payments from customers, which could impact cash flow and liquidity.
Business Update

United Therapeutics Makes History with Successful Xenothymokidney Transplant: Paving the Way for a New Era in Transplantation.

Published Wed, Apr 24 2024 1:47 PM UTC

United Therapeutics Achieves Historic Milestone with First Successful Xenothymokidney TransplantOn April 12, 2024, United Therapeutics Corporation, a public benefit corporation, made history by successfully completing the world s first xenothymokidney transplant. This groundbreaking procedure marked a significant achievement in the field of transplantation and signifies a ma...
United Therapeutics Corporation

United Therapeutics Corporation Rises Above the Sinking Major Pharmaceutical Preparations Industry, Achieving Spectacular Revenue Surge and Steady Profitability Growth in Q3 2023.

United Therapeutics Corporation has emerged as a shining star in the third quarter of 2023, standing tall amidst a struggling Major Pharmaceutical Preparations sector. With a remarkable double-digit revenue advance of 18.101% to $609.40 million, the company has showcased its resilience and ability to navigate through challenging times.
In addition to the impressive revenue growth, United Therapeutics Corporation also experienced a modest profitability advance of 9.57% to $5.38 per share. This exceptional performance not only demonstrates the company's strong financial footing but also showcases its ability to generate consistent profits.
United Therapeutics Corporation

United Therapeutics Corporation Witnesses Remarkable Revenue Surge in Recent Fiscal Period, Outperforms Pharmaceutical Industry Peers

United Therapeutics Corporation has showcased impressive financial results in its most recent fiscal period, with a significant increase in both earnings per share and revenue. Earnings per share more than doubled by 117.43% year on year, reaching $5.24 per share, while revenue grew by 27.758% to $596.50 million. This performance has surpassed that of its industry peers, as the Major Pharmaceutical Preparations industry only experienced a 3.96% top-line advance during the same period.
The company's sequential income also improved by 7.82% from $4.86 per share, and revenue increased by 17.676% from $506.90 million. Such growth is evident in the net profits that soared to $259.200 million in the April to June 30, 2023 fiscal interval, a staggering 123.45% increase compared to the same period a year ago when net earnings reached $116.000 million.






United Therapeutics's Segments
Tyvaso DPI    36.67 % of total Revenue
Nebulized Tyvaso    21.26 % of total Revenue
Remodulin    17.13 % of total Revenue
Orenitram    15.12 % of total Revenue
Unituxin    8.16 % of total Revenue
Adcirca    0.93 % of total Revenue
Other    0.73 % of total Revenue
Total Tyvaso    57.92 % of total Revenue
U S    95.78 % of total Revenue
U S Total Tyvaso    56.06 % of total Revenue
U S Tyvaso DPI    36.67 % of total Revenue
U S Nebulized Tyvaso    19.39 % of total Revenue
U S Remodulin    15.41 % of total Revenue
U S Orenitram    15.12 % of total Revenue
U S Unituxin    7.69 % of total Revenue
U S Adcirca    0.93 % of total Revenue
U S Other    0.57 % of total Revenue
ROW    4.22 % of total Revenue
ROW Total Tyvaso    1.87 % of total Revenue
ROW Nebulized Tyvaso    1.87 % of total Revenue
ROW Remodulin    1.72 % of total Revenue
ROW Unituxin    0.47 % of total Revenue
ROW Other    0.16 % of total Revenue





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com